Evidence map›Paper›PMID 37927354›Full record

ArticleMedicine international

Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report.

Ertugrul Bayram, Tugba Toyran, Burak Güney, Aysun Hatice Uguz, Derya Gümürdülü, Semra Paydas

Abstract readCase Reports
In one paragraph

Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ertugrul BayramDepartment of Medical Oncology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.
Tugba ToyranDepartment of Pathology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.
Burak GüneyDepartment of Nuclear Medicine, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.
Aysun Hatice UguzDepartment of Pathology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.
Derya GümürdülüDepartment of Pathology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.
Semra PaydasDepartment of Medical Oncology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a common malignancy that has usually already metastasized at the time of diagnosis; however, thyroid metastases are extremely rare. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion has been observed in 3-7% of cases of lung adenocarcinoma. ALK inhibitor therapy has been shown to exert a positive effect on disease progression. The present study describes the case of a patient with ALK-positive non-small cell lung carcinoma and thyroid metastases who exhibited a minimal response to ALK inhibitor therapy in the primary lesion, but had a complete pathological response in the thyroid, as confirmed by a thyroid biopsy. The present case report undermines the need for further evidence from genomic testing following this different tumor course in thyroid tissue.

Indexed as

alectiniblung cancertreatmenttumor heterogeneity

Identifiers

PMID37927354
PMCPMC10620843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.